Joel Corrêa da Rosa

Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis

BACKGROUND: Atopic dermatitis (AD) is characterized by microbial dysbiosis, notably an overabundance of Staphylococcus species. This study aimed to evaluate the effects of abrocitinib, a Janus kinase 1-selective inhibitor, on the skin microbiome and clinical outcomes in patients...